Zytorvi — Toripalimab
Toripalimab is an anti-PD-1 checkpoint inhibitor that's built a particularly strong clinical reputation in nasopharyngeal carcinoma, a cancer with disproportionately high incidence in parts of Southeast Asia and Southern China compared to most of the rest of the world — a regional disease pattern that makes this specific SKU strategically valuable for our Southeast Asia distributor relationships beyond its broader oncology approval base.
- Approved indications: Nasopharyngeal carcinoma, and other advanced solid tumors depending on regional approval status
- Mechanism: Blocks the PD-1 checkpoint, restoring the immune system's ability to recognize and attack cancer cells, similar in mechanism to Nivolumab and Tislelizumab in our catalogue
- Regional clinical significance: Particularly strong efficacy data in nasopharyngeal carcinoma, a cancer type with meaningfully higher incidence in parts of Southeast Asia and Southern China than in Western populations
- Combination therapy: Often used alongside chemotherapy in first-line treatment settings
Key Product Facts
240mg
Strength
Single-dose vial
Pack Size
Toripalimab
Active Ingredient
Oncology
Category
On Request
Availability
Toripalimab is an anti-PD-1 checkpoint inhibitor that's built a particularly strong clinical reputation in nasopharyngeal carcinoma, a cancer with disproportionately high incidence in parts of Southeast Asia and Southern China compared to most of the rest of the world — a regional disease pattern that makes this specific SKU strategically valuable for our Southeast Asia distributor relationships beyond its broader oncology approval base.
- Approved indications: Nasopharyngeal carcinoma, and other advanced solid tumors depending on regional approval status
- Mechanism: Blocks the PD-1 checkpoint, restoring the immune system's ability to recognize and attack cancer cells, similar in mechanism to Nivolumab and Tislelizumab in our catalogue
- Regional clinical significance: Particularly strong efficacy data in nasopharyngeal carcinoma, a cancer type with meaningfully higher incidence in parts of Southeast Asia and Southern China than in Western populations
- Combination therapy: Often used alongside chemotherapy in first-line treatment settings
- Immune-related adverse events: Same class-effect risk profile as other PD-1 inhibitors — pneumonitis, colitis, hepatitis, and endocrine dysfunction possible, requiring ongoing monitoring
- Pregnancy: Contraindicated
- Vaccination: Live vaccines should be avoided during treatment
- Monitoring: Baseline and periodic thyroid, liver, and pulmonary function assessment recommended
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: Available on request | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export
- Coverage: Global, with particular strength in Southeast Asian markets
- Tracking: Full shipment tracking included
What is Toripalimab used for?
Treats nasopharyngeal carcinoma and other advanced solid tumors by activating the immune system against cancer cells.
Get Toripalimab price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Why is it particularly relevant for Southeast Asia?
Nasopharyngeal carcinoma has notably higher incidence in parts of Southeast Asia and Southern China, and Toripalimab has shown strong efficacy data specifically in this cancer type.
Is it chemotherapy?
No, it's an immune checkpoint inhibitor that works by activating the immune system, distinct from traditional chemotherapy.
Who supplies Toripalimab from India?
WHO-GMP certified manufacturing partners with full export documentation.
